title: Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
authors.forename: S
authors.initials: S
authors.lastname: Corm
authors.forename: V
authors.initials: V
authors.lastname: Biggio
authors.forename: C
authors.initials: C
authors.lastname: Roche-Lestienne
authors.forename: J-L
authors.initials: JL
authors.lastname: Laï
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: N
authors.initials: N
authors.lastname: Philippe
authors.forename: F-E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: C
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016313:Genes, abl; D014644:Genetic Variation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; C493728:RUNX1 protein, human; D014157:Transcription Factors; D000068877:Imatinib Mesylate